DexCom, Inc. (NASDAQ:DXCM) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by Francis Steltz on Aug 6th, 2026

DexCom, Inc. (NASDAQ:DXCM – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twenty-seven brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, twenty-one have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $88.7083.

A number of analysts have weighed in on DXCM shares. Mizuho increased their price objective on DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Stifel Nicolaus set a $95.00 price target on DexCom and gave the stock a “buy” rating in a research note on Friday, July 31st. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the stock a “buy” rating in a report on Monday. Truist Financial set a $93.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Barclays reiterated an “underweight” rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a research report on Monday, May 18th.

Check Out Our Latest Analysis on DexCom

DexCom Trading Down 4.9%

NASDAQ DXCM opened at $82.66 on Thursday. The firm’s fifty day moving average is $73.99 and its two-hundred day moving average is $69.53. DexCom has a one year low of $54.11 and a one year high of $87.85. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The firm has a market cap of $31.19 billion, a PE ratio of 32.67, a P/E/G ratio of 1.45 and a beta of 1.41.

DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business’s revenue was up 13.1% on a year-over-year basis. During the same quarter last year, the company posted $0.48 earnings per share. Analysts expect that DexCom will post 2.65 earnings per share for the current year.

Insider Activity

In related news, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $74.13, for a total value of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares in the company, valued at $7,075,708.50. This trade represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 102,506 shares of company stock worth $7,535,898 in the last ninety days. 0.28% of the stock is currently owned by insiders.

Institutional Trading of DexCom

Several hedge funds have recently modified their holdings of DXCM. Reflection Asset Management purchased a new stake in shares of DexCom in the fourth quarter valued at approximately $25,000. Ascentis Independent Advisors purchased a new position in DexCom in the first quarter worth $25,000. MCF Advisors LLC purchased a new position in DexCom in the fourth quarter worth $32,000. Wellington Grp LLC raised its position in DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after acquiring an additional 475 shares in the last quarter. Finally, DV Equities LLC acquired a new stake in DexCom in the fourth quarter valued at $36,000. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

(Get Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.